Suppr超能文献

活减毒麻疹疫苗在造血干细胞移植受者和实体器官移植受者中的安全性和有效性。

Safety and efficacy of early vaccination with live attenuated measles vaccine for hematopoietic stem cell transplant recipients and solid organ transplant recipients.

机构信息

University of Utrecht & Wilhelmina Children's Hospital, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.

Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, Lundlaan 6, 3584 EA Utrecht, the Netherlands.

出版信息

Vaccine. 2021 Jun 8;39(25):3338-3345. doi: 10.1016/j.vaccine.2021.04.049. Epub 2021 May 12.

Abstract

BACKGROUND AND OBJECTIVE

Vaccination with the live attenuated measles vaccine is currently recommended two years after hematopoietic stem cell transplantation (HSCT) and generally contraindicated after solid organ transplantation (SOT) due to safety concerns. However, in the last few years new data on the administration of the measles vaccine to HSCT recipients less two years post-transplantation and to SOT recipients have become available. This new data may change current guidelines and practices. The objective of this review is to provide an overview of the current data on the safety and efficacy of early measles vaccination for HSCT- and SOT recipients.

METHOD

PubMed and EMBASE were searched from the earliest date available through October 2019 to identify all research that reported on the safety and efficacy of measles vaccination after SOT or less than two years after HSCT.

RESULTS

A total of ten studies was included in this review. In the six studies that evaluated the efficacy of measles vaccination after SOT, seroconversion rates ranged from 41 to 100% after one dose and 73 to 100% after two doses. In the four studies that evaluated the efficacy of measles vaccination less than two years after HSCT, seroconversion rates ranged from 33 to 100% after one dose and 100% after two doses. In all studies, the administration of the measles vaccine after transplantation was considered to be safe. There were no cases of infection with the attenuated vaccine strain, and there were no adverse events related to the vaccination.

CONCLUSION

Data on the administration of the measles vaccine after SOT and less than two years after HSCT is scarce. However, the current data available suggest that it is efficacious and well tolerable. Therefore, early measles vaccination could be considered in selected groups of SOT- and HSCT recipients during increased measles transmission or an outbreak setting.

摘要

背景和目的

由于安全性方面的考虑,目前建议在造血干细胞移植(HSCT)后两年接种减毒麻疹疫苗,且一般禁忌在实体器官移植(SOT)后接种。然而,在过去几年中,有关在 HSCT 后少于两年和 SOT 受者中接种麻疹疫苗的新数据已经出现。这些新数据可能会改变当前的指南和实践。本综述的目的是提供对 HSCT 和 SOT 受者早期接种麻疹疫苗的安全性和有效性的最新数据概述。

方法

通过检索 PubMed 和 EMBASE,从最早的可用日期到 2019 年 10 月,查找所有报告 SOT 后或 HSCT 后不到两年接种麻疹疫苗的安全性和有效性的研究。

结果

本综述共纳入 10 项研究。在评估 SOT 后麻疹疫苗有效性的 6 项研究中,一剂接种后的血清转化率为 41%至 100%,两剂接种后的血清转化率为 73%至 100%。在评估 HSCT 后不到两年麻疹疫苗有效性的 4 项研究中,一剂接种后的血清转化率为 33%至 100%,两剂接种后的血清转化率为 100%。在所有研究中,认为移植后接种麻疹疫苗是安全的。没有减毒疫苗株感染的病例,也没有与疫苗接种相关的不良事件。

结论

关于 SOT 后和 HSCT 后不到两年接种麻疹疫苗的数据很少。然而,目前可用的数据表明其有效且耐受良好。因此,在麻疹传播增加或暴发期间,可考虑在某些 SOT 和 HSCT 受者群体中进行早期麻疹疫苗接种。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验